ASTRO Annual Meeting
ASTRO Annual Meeting
October 04, 2011
1 min read
Save

Accelerated IMRT with concurrent boost resulted in good local control, OS in breast cancer

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

2011 ASTRO Annual Meeting

MIAMI - In patients with breast cancer who were treated with a regimen of accelerated intensity modulated radiation therapy with a concurrent boost to the tumor bed, the local control rate was 98.6% and the OS was 97.6%.

From 2003 to 2006, researchers, including Etin-Osa O. Osa, MD, from the New York University Clinical Cancer Center, evaluated 490 patients with stage 0, I or II breast cancer who were prospectively enrolled in two consecutive protocols. The patients had received radiotherapy after a segmental mastectomy and had negative margins of tumor excisions.

Accelerated intensity modulated radiation included a total dose of 40.5 Gy, delivered in 15 fractions at 2.7 Gy per fraction. The patients received treatment Monday to Friday for 3 weeks, and received a concomitant daily boost of 0.5 Gy to the tumor site. The majority of women, 93%, were treated in the prone position, and the remaining 7% were treated in the supine position.

Most of the patients, 82%, had stage I or II invasive breast cancer and 18% had ductal carcinoma in situ. After a median follow-up of 3 years, seven patients had a local recurrence, resulting in 98.6% local control. Five additional patients developed distant recurrence and four others developed contralateral breast cancer.

There were 12 total deaths, five of which were breast cancer-related, resulting in a 97.6% OS. An evaluation of late radiation toxicity showed that 57% of the patients experience grade-1 toxicity, 18% experienced grade-2 toxicity, 3% experienced grade-3 toxicity and 22% had no toxicity. A self evaluation of cosmesis showed that 83% of the patients reported a good-excellent result, 16% a fair result and 1% a poor result.

Earn CME this spring at the HemOnc Today Breast Cancer Review & Perspective meeting to be held March 23-24, 2012 at the Hilton San Diego Bayfront. See details at HemOncTodayBreastCancer.com.

For more information:

  • Osa EO. #17. Presented at: the 53rd ASTRO Annual Meeting; Oct. 2-6, 2011; Miami Beach, Fla.

Disclosure: Dr. Osa reports no relevant financial disclosures.

Twitter Follow HemOncToday.com on Twitter.